Biogen and Denali sign Parkinson’s drug deal worth $2bn
Biogen Inc. and Denali Therapeutics Inc. announced that they have signed a binding agreement to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat…
Read More...
Read More...
